Reevaluation Of Systemic Early Neuromuscular Blockade
Status:
Completed
Trial end date:
2019-04-04
Target enrollment:
Participant gender:
Summary
This study evaluates whether giving a neuromuscular blocker (skeletal muscle relaxant) to a
patient with acute respiratory distress syndrome will improve survival. Half of the patients
will receive a neuromuscular blocker for two days and in the other half the use of
neuromuscular blockers will be discouraged.